Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q1 2021 · 10-Q
Revenue$191.22K$191.22K+237.0% vs Q1 2020 Net Income-$1.35M-$1.35MN/M vs Q1 2020 EPS Diluted-$0.15-$0.15N/M vs Q1 2020 Operating Income-$1,369,091N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Margins · derivedOperating margin-716.0%+1452.8 pt vs Q1 2020
Net margin-703.9%+1374.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 11, 2021 · 41 d after period end